• Pharming reaffirmed full-year revenue guidance of USD 405 million to USD 425 million, projecting 8% to 13% growth.
• Operating expense guidance was maintained at USD 330 million to USD 335 million, implying 6% to 8% growth.
• First-quarter revenue fell 8%, driven by a 15% drop in RUCONEST revenue to USD 58.4 million from USD 68.6 million, reflecting inventory drawdowns and a planned exit from certain non-U.S. markets.
• Joenja revenue rose 34% to USD 11.5 million from USD 9.5 million, with U.S. patients on therapy increasing to 127 from 102 a year earlier.
• Pipeline milestones highlighted EU momentum for Joenja in APDS following a positive CHMP opinion, targeted Phase II readouts for leniolisib in immune-dysregulation PIDs in H2 2026, and planned completion of enrollment in H2 2026 for napazimone’s pivotal FALCON study in mtDNA mitochondrial disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein.